ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma
Latest Information Update: 13 Jan 2023
At a glance
- Drugs Bendamustine (Primary) ; Lenalidomide; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON110FL-GLSG-NCRI; ReBeL
- 13 Dec 2022 Status changed from recruiting to discontinued, as per Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 18 Aug 2015 Planned End Date changed from 1 Oct 2025 to 1 Oct 2015, as reported by United Kingdom Clinical Research Network.